Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KRAS-EphA-2-CAR-DC Vaccine + ICIs in Advanced Solid Tumors
NCT05631899Phase 1Active, not recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Modality
- Whole Cell Cancer Vaccines, CAR-T Cells, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of KRAS-EphA-2-CAR-DC in solid tumor (3 arms), sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of treatment related adverse events at 2 years, Clinical Response at 2 years and 2 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
KRAS-EphA-2-CAR-DC
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05631899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631899.